Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 5/20 | 0.36 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.36 |
| ▸ | RARB | P10826 | 8/20 | 0.36 |
| ▸ | RARG | P13631 | 8/20 | 0.36 |
| ▸ | RARA | P10276 | 7/20 | 0.36 |
| ▸ | RXRA | P19793 | 5/20 | 0.36 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.33 |
| ▸ | GMNN | O75496 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7630266 | 0.88 | RARB (0.36) | ALKRARBRARGRARARXRA | |
| SCHEMBL1809356 | 0.78 | RARB (0.34) | ALKRARBRARGRARARXRA | |
| SCHEMBL11971277 | 0.78 | RARB (0.34) | ALKRARBRARGRARARXRA | |
| SCHEMBL11971275 | 0.78 | RARB (0.34) | ALKRARBRARGRARARXRA | |
| SCHEMBL5648628 | 0.77 | PGR (0.49) | PGRKDM4EALDH1A1CYP1A2POLB | |
| SCHEMBL24055007 | 0.76 | PGR (0.50) | PGRSRD5A1 | |
| SCHEMBL3893981 | 0.76 | MALT1 (0.41) | PGRESR1ESR2 | |
| SCHEMBL1806400 | 0.76 | PBRM1 (0.49) | KDM4EALDH1A1LMNACYP3A4ESR1 | |
| SCHEMBL15717088 | 0.76 | MALT1 (0.41) | PGRSRD5A1CYP1A2CYP2C19 | |
| SCHEMBL4585571 | 0.74 | RARB (0.53) | RARBRARGRARARXRAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2592071-B1 | Tricyclic heterocyclic compounds | BRISTOL MYERS SQUIBB CO (US) | 2019-09-18 | — | — | EP | disclosed |
| EP-2592071-B1 | Tricyclic heterocyclic compounds | BRISTOL MYERS SQUIBB CO (US) | 2019-09-18 | — | — | EP | disclosed |
| US-9216972-B2 | Tricyclic heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-22 | — | — | US | disclosed |
| US-9216972-B2 | Tricyclic heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-22 | — | — | US | disclosed |
| US-9216972-B2 | Tricyclic heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-22 | — | — | US | disclosed |
| CN-102686571-B | tricyclic heterocyclic compounds | BRISTOL-MYERS SQUIBB CO. (US) | 2015-11-25 | — | — | CN | disclosed |
| EP-2592071-A1 | Tricyclic heterocyclic compounds | Bristol-Myers Squibb Company (US) | 2013-05-15 | — | — | EP | disclosed |
| EP-2592071-A1 | Tricyclic heterocyclic compounds | Bristol-Myers Squibb Company (US) | 2013-05-15 | — | — | EP | disclosed |
| EP-2493866-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS | Bristol-Myers Squibb Company (US) | 2012-09-05 | — | — | EP | disclosed |
| US-20120214767-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-23 | — | — | US | disclosed |
| US-20120214767-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-23 | — | — | US | disclosed |
| US-20120214767-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-23 | — | — | US | disclosed |
| WO-2011059784-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011059784-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214767-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS | S1PR1, S1PR3, TBXA2R | PGR 1429/4885ALK 3040/4885RARB 2937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.